Skip to main navigation Skip to search Skip to main content

A Phase II, Double-Blind, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar12 in Healthy Infants

Upstate Medical University

Project: Research

Project Details

StatusFinished
Effective start/end date02/2/17 → 02/1/21

Funding

  • Merck Sharp and Dohme Limited Liability Corporation: $133,208.40